Cell surface biogenesis in Streptococcus pneumoniae
肺炎链球菌的细胞表面生物合成
基本信息
- 批准号:10543050
- 负责人:
- 金额:$ 43.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-01-01 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:AdoptedAntibiotic TherapyAntibioticsAreaAutolysisBacillus subtilisBacteriaBiochemicalBiochemistryBiogenesisBiologicalBiologyCell CycleCell WallCell surfaceCellsCessation of lifeChildCleaved cellComplexCytolysisDevelopmentDiseaseDrug TargetingDrug resistanceElderlyEnzymesEscherichia coliExposure toFutureGeneticGenetic ScreeningGenetic studyGram-Positive BacteriaGrowthHomologous GeneHydrolaseIncidenceInfectionInnate Immune SystemJointsKnowledgeLaboratoriesLifeMembrane ProteinsMethodsMicroscopyModelingModernizationMolecular ProfilingMorphogenesisMorphologyN-Acetylmuramoyl-L-alanine AmidaseOrganismPathogenesisPathway interactionsPatternPenicillin-Binding ProteinsPeptidesPeptidoglycanPeptidoglycan glycosyltransferasePeptidyltransferasePharmaceutical PreparationsPhasePhosphorylationPhosphotransferasesPlayPneumococcal vaccinePneumoniaPolymersPolysaccharidesProcessProteinsPublishingReactionRegulationResearchResistanceRodRoleShapesStaphylococcus aureusStreptococcus pneumoniaeStressStructureSurfaceSystemTeichoic AcidsTestingVaccine TherapyVaccinesVirulenceVirulence FactorsWorkbeta-Lactamscell envelopecrosslinkenzyme activityexperimental studygenetic analysishuman pathogenin vitro activityinsightlipoteichoic acidmodel organismnovelpathogenpathogenic bacteriapolymerizationpolypeptidepreventprogramsreconstitutionresponsesuccesstherapeutic developmentvaccine-induced immunityvirtual
项目摘要
PROJECT SUMMARY
The cell surface of pathogenic bacteria contains many key virulence factors that are used to interface with the
host. Cell surface polymers also contain the molecular signatures recognized by the innate immune system to
activate a defensive response, and surface molecules or their biogenesis pathways serve as important targets
for many of our most effective vaccine and antibiotic therapies. A better understanding of the mechanisms
responsible for bacterial surface assembly will therefore impact virtually all areas of pathogenesis research and
inform the development of new treatments for infections. Although some aspects of cell surface assembly can
be inferred from studies of non-pathogenic organisms, results from the models will never be entirely predictive.
Departures from the model are likely to be especially pronounced for pathogens like Streptococcus
pneumoniae (Sp) that adopt a different (ovoid) morphology and grow via distinct mechanisms from rod-shaped
organisms like Escherichia coli and Bacillus subtilis where studies of cell surface assembly have traditionally
been investigated. Sp is a major cause of life-threatening disease in young children and older adults, and the
incidence of drug-resistant infections with this organism is on the rise. The efficacy of the polyvalent Sp
vaccine is also declining due to the emergence of strains with altered surface polysaccharides that escape
vaccine-induced immunity. It is therefore important to identify new ways of disabling Sp growth. To do so, we
have initiated a program to investigate cell surface assembly in Sp that leverages the joint expertise of the
Rudner and Bernhardt laboratories in cell wall biogenesis, gram-positive biology, microscopy, biochemistry,
and genetics. Importantly, our approach is not limited to the characterization of homologs of well-studied cell
morphogenesis factors from the rod-shaped model organisms. Instead we are taking advantage of forward
genetic screens powered by modern sequencing methods to discover new players and biological mechanisms
involved in Sp growth. Our preliminary genetic analyses have uncovered two novel regulators of the penicillin-
binding proteins (PBPs) of Sp. These are the first set of factors identified in gram-positive bacteria that control
the activity of these critical cell wall synthases. The first aim of the project will investigate the mechanism by
which these factors modulate PBP activity and connect the function of these enzymes with other components
of the morphogenetic system. In addition to controlling PBP activity, proper surface assembly also requires the
regulation of enzymes that cleave the cell wall. The factors governing the activity of these enzymes are poorly
understood in all bacteria. Our second aim will build on promising results where we have identified a regulatory
role for surface polymers called lipoteichoic acids (LTAs) in controlling the activity of the cell wall hydrolase
LytA responsible for Sp cell lysis following beta-lactam treatment. Overall, our results promise to uncover new
ways of either blocking cell wall assembly or triggering autolysis for therapeutic development.
项目摘要
病原菌的细胞表面含有许多关键的毒力因子,这些毒力因子被用来与病原菌相互作用。
主持人细胞表面聚合物还含有由先天免疫系统识别的分子特征,
激活防御反应,表面分子或其生物合成途径是重要的靶点
我们许多最有效的疫苗和抗生素疗法。更好地理解机制
因此,负责细菌表面组装的基因将影响致病机理研究的几乎所有领域,
为开发新的感染治疗方法提供信息。尽管细胞表面组装的某些方面可以
虽然这些模型不能从非致病性生物体的研究中推断出来,但模型的结果永远不会完全具有预测性。
该模型的结果可能对链球菌等病原体特别明显
肺炎链球菌(Sp),采用不同的(卵形)形态,并通过不同的机制从杆状生长
像大肠杆菌和枯草芽孢杆菌这样的生物,传统上对细胞表面组装的研究
被调查了在幼儿和老年人中,Sp是威胁生命的疾病的主要原因,
这种微生物的抗药性感染的发生率正在上升。多价Sp的功效
疫苗也在下降,因为出现了表面多糖改变的菌株,
疫苗诱导免疫因此,重要的是要找到新的方法来抑制Sp的生长。为此,我们
已经启动了一项计划,以调查细胞表面组装在Sp,利用联合专业知识的
鲁珀特和伯恩哈特实验室在细胞壁生物发生,革兰氏阳性生物学,显微镜,生物化学,
和遗传学。重要的是,我们的方法并不局限于研究细胞的同源物的特性。
杆状模式生物的形态发生因子。相反,我们正在利用前进
由现代测序方法提供动力的基因筛选,以发现新的参与者和生物机制
参与Sp的生长。我们初步的基因分析发现了两种新的青霉素调节剂-
这些是在革兰氏阳性菌中发现的第一组因子,
这些关键细胞壁脱氢酶的活性。该项目的第一个目标是通过以下方式调查该机制:
这些因子调节PBP活性并将这些酶的功能与其他组分联系起来
形态发生系统。除了控制PBP活性之外,适当的表面组装还需要
调节切割细胞壁的酶。控制这些酶活性的因素很差,
在所有细菌中都是如此。我们的第二个目标将建立在有希望的结果,我们已经确定了一个监管
称为脂磷壁酸(LTA)的表面聚合物在控制细胞壁水解酶活性中的作用
LytA负责β-内酰胺处理后的Sp细胞裂解。总的来说,我们的研究结果有望揭示新的
阻断细胞壁组装或引发自溶以用于治疗开发的方法。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
WhyD tailors surface polymers to prevent premature bacteriolysis and direct cell elongation in Streptococcus pneumoniae.
- DOI:10.7554/elife.76392
- 发表时间:2022-05-20
- 期刊:
- 影响因子:7.7
- 作者:Flores-Kim, Josue;Dobihal, Genevieve S.;Bernhardt, Thomas G.;Rudner, David Z.
- 通讯作者:Rudner, David Z.
MacP bypass variants of Streptococcus pneumoniae PBP2a suggest a conserved mechanism for the activation of bifunctional cell wall synthases.
- DOI:10.1128/mbio.02390-23
- 发表时间:2023-12-19
- 期刊:
- 影响因子:6.4
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID Z RUDNER其他文献
DAVID Z RUDNER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID Z RUDNER', 18)}}的其他基金
Identification and characterization of a comprehensive set of factors required for sporulation and germination in Bacillus anthracis
炭疽芽孢杆菌孢子形成和萌发所需的一系列综合因素的鉴定和表征
- 批准号:
10510204 - 财政年份:2022
- 资助金额:
$ 43.01万 - 项目类别:
Growth and differentiation in Bacillus subtilis
枯草芽孢杆菌的生长和分化
- 批准号:
10630235 - 财政年份:2022
- 资助金额:
$ 43.01万 - 项目类别:
Growth and differentiation in Bacillus subtilis
枯草芽孢杆菌的生长和分化
- 批准号:
10404754 - 财政年份:2022
- 资助金额:
$ 43.01万 - 项目类别:
Identification and characterization of a comprehensive set of factors required for sporulation and germination in Bacillus anthracis
炭疽芽孢杆菌孢子形成和萌发所需的一系列综合因素的鉴定和表征
- 批准号:
10632069 - 财政年份:2022
- 资助金额:
$ 43.01万 - 项目类别:
Cell Envelope Homeostasis in Bacillus subtilis
枯草芽孢杆菌的细胞包膜稳态
- 批准号:
10335184 - 财政年份:2019
- 资助金额:
$ 43.01万 - 项目类别:
Cell Envelope Homeostasis in Bacillus subtilis
枯草芽孢杆菌的细胞包膜稳态
- 批准号:
10093999 - 财政年份:2019
- 资助金额:
$ 43.01万 - 项目类别:
Cell surface biogenesis in Streptococcus pneumoniae
肺炎链球菌的细胞表面生物合成
- 批准号:
10318928 - 财政年份:2019
- 资助金额:
$ 43.01万 - 项目类别:
Fluorescence Microscope for Time-Lapse Imaging of Bacteria
用于细菌延时成像的荧光显微镜
- 批准号:
7792067 - 财政年份:2010
- 资助金额:
$ 43.01万 - 项目类别:
相似海外基金
SBIR Phase II: Development of a urine dipstick test that can guide immediate and appropriate antibiotic therapy for treatment of complicated urinary tract infections
SBIR II 期:开发尿液试纸测试,可以指导复杂尿路感染的立即和适当的抗生素治疗
- 批准号:
2213034 - 财政年份:2023
- 资助金额:
$ 43.01万 - 项目类别:
Cooperative Agreement
Personalized Antibiotic Therapy in the Emergency Department: PANTHER Trial
急诊科的个性化抗生素治疗:PANTHER 试验
- 批准号:
10645528 - 财政年份:2023
- 资助金额:
$ 43.01万 - 项目类别:
Strategies for improving the efficacy of combinatorial antibiotic therapy in chronic infections
提高慢性感染联合抗生素治疗疗效的策略
- 批准号:
10736285 - 财政年份:2023
- 资助金额:
$ 43.01万 - 项目类别:
A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures
一种治疗感染性骨折的新型骨靶向抗生素疗法
- 批准号:
10603486 - 财政年份:2023
- 资助金额:
$ 43.01万 - 项目类别:
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
- 批准号:
449379 - 财政年份:2020
- 资助金额:
$ 43.01万 - 项目类别:
Studentship Programs
Sex-Specific Differences in End-of-Life Burdensome Interventions and Antibiotic Therapy in Nursing Home Residents With Advanced Dementia
患有晚期痴呆症的疗养院居民的临终干预和抗生素治疗的性别差异
- 批准号:
422034 - 财政年份:2020
- 资助金额:
$ 43.01万 - 项目类别:
Optimizing outpatient parenteral antibiotic therapy to support hospital-in-the-home program across the unique environmental conditions of Australia
优化门诊肠外抗生素治疗,以支持澳大利亚独特环境条件下的家庭医院计划
- 批准号:
nhmrc : 1197866 - 财政年份:2020
- 资助金额:
$ 43.01万 - 项目类别:
Investigator Grants
Resistance evolution in the presence of combination antibiotic therapy
联合抗生素治疗下耐药性的演变
- 批准号:
2241853 - 财政年份:2019
- 资助金额:
$ 43.01万 - 项目类别:
Studentship
Host-pathogen interactions in antibiotic therapy for listeriosis
李斯特菌病抗生素治疗中宿主与病原体的相互作用
- 批准号:
18K07106 - 财政年份:2018
- 资助金额:
$ 43.01万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Multipurpose targeted nano-antibiotic therapy to fight tough infection in bones
多用途靶向纳米抗生素疗法可对抗骨骼中的严重感染
- 批准号:
9788269 - 财政年份:2018
- 资助金额:
$ 43.01万 - 项目类别:














{{item.name}}会员




